Elubrixin tosylate

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameElubrixin tosylate
Drug Alias Name依芦立辛ElubrixinumElubrixina依鲁利星elubrixin +[9
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-X-C motif chemokine receptor 2 antagonists
TargetsC-X-C motif chemokine receptor 2
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesNetherlands +[7
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsPulmonary Disease, Chronic ObstructiveCystic FibrosisColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksKEGG